TORNTPHARM
OVERVALUEDTorrent Pharmaceuticals
Pharma · NSE
↓ 231.2% vs fair value
52W Low
₹3,102
+45.0% from low
52W High
₹4,555
-1.3% from high
Valuation Gauge
Current Price
₹4,497
Fair Value
₹1,358
Fair Value Analysis
₹1,358
Based on free cash flow projections and earnings growth potential for Pharma sector companies | Sector-expensive: P/E at 80th percentile vs sector peers. | ROCE improving (latest 34.5%) — capital allocation becoming more efficient.
Cash Flow Analysis
38% weight
Growth Valuation
63% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Healthy
Profitability
ROE of 26.9% is above the Pharma sector benchmark of 18% — strong returns
Debt & Leverage
D/E ratio of 0.3x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 65.3x trades at a significant premium to Pharma sector median (42x)
Cash Flow
FCF margin of 17.4% — exceptional cash generation (₹1,973 Cr)
Earnings Growth
5yr EPS CAGR of 35.0% is well above the Pharma sector average of 15.3% — strong growth
Dividend
Dividend yield of 0.8% provides moderate shareholder returns
Company Health Timeline
10-year financial health at a glance
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
1.4%
Free cash flow / market cap
Revenue Growth (YoY)
+17.6%
Year-on-year revenue change
Profit Growth (YoY)
+26.2%
Year-on-year PAT change
Operating Cash Flow
₹2.6K Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹67.1
P/E Ratio
65.3x
P/B Ratio
17.6x
ROE
26.9%
ROCE
28.5%
Debt / Equity
0.33x
Beta
0.15
Div Yield
0.8%
FCF (Cr)
₹1,973 Cr
Revenue (Cr)
₹11,317 Cr
EPS Growth 5Y
35%
Mkt Cap (Cr)
₹1,49,109 Cr
52W High
₹4,555.1
52W Low
₹3,102
Book Value/Share
₹249.6
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹12.7K Cr | ₹4.2K Cr | 33.0% | ₹2.3K Cr | ₹67.12 |
| 2025-03-31 | ₹11.5K Cr | ₹3.7K Cr | 32.0% | ₹1.9K Cr | ₹56.47 |
| 2024-03-31 | ₹10.7K Cr | ₹3.4K Cr | 31.0% | ₹1.7K Cr | ₹48.94 |
| 2023-03-31 | ₹9.6K Cr | ₹2.8K Cr | 30.0% | ₹1.2K Cr | ₹36.79 |
| 2022-03-31 | ₹8.5K Cr | ₹2.4K Cr | 29.0% | ₹777 Cr | ₹22.97 |
| 2021-03-31 | ₹8.0K Cr | ₹2.5K Cr | 31.0% | ₹1.3K Cr | ₹36.99 |
| 2020-03-31 | ₹7.9K Cr | ₹2.2K Cr | 27.0% | ₹1.0K Cr | ₹30.28 |
| 2019-03-31 | ₹7.7K Cr | ₹2.0K Cr | 26.0% | ₹436 Cr | ₹12.89 |
| 2018-03-31 | ₹6.0K Cr | ₹1.3K Cr | 23.0% | ₹678 Cr | ₹20.04 |
| 2017-03-31 | ₹5.8K Cr | ₹1.4K Cr | 24.0% | ₹934 Cr | ₹27.59 |
| 2016-03-31 | ₹6.7K Cr | ₹2.7K Cr | 41.0% | ₹1.7K Cr | ₹51.22 |
| 2015-03-31 | ₹4.6K Cr | ₹1.0K Cr | 22.0% | ₹751 Cr | ₹22.19 |
| 2014-03-31 | ₹4.2K Cr | ₹955 Cr | 23.0% | ₹664 Cr | ₹19.62 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86.4 | ₹469.7 | +81.6% | 7.7 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹118.2 | ₹237.8 | +50.3% | 26.8 | 5.2% | FAIRLY_VALUED |
Bal Pharma Limited | ₹82.3 | ₹147.5 | +44.2% | 15.7 | 12.6% | FAIRLY_VALUED |
Lincoln Pharmaceuticals Limited | ₹732.1 | ₹1,131.6 | +35.3% | 14.7 | 13.1% | FAIRLY_VALUED |
Zydus Lifesciences | ₹1,038.6 | ₹1,502.2 | +30.9% | 20.6 | 19.9% | UNDERVALUED |
Lupin | ₹2,270.7 | ₹3,112 | +27.0% | 19.5 | 26.9% | UNDERVALUED |
Natco Pharma | ₹1,170 | ₹1,571.3 | +25.5% | 13.8 | 18.0% | UNDERVALUED |
Sudeep Pharma Limited | ₹675 | ₹739.2 | +8.7% | 43.7 | 21.4% | FAIRLY_VALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant